Supernus Pharmaceuticals Total Current Assets 2011-2024 | SUPN
Supernus Pharmaceuticals total current assets from 2011 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Supernus Pharmaceuticals Annual Total Current Assets
(Millions of US $) |
| 2023 |
$493 |
| 2022 |
$734 |
| 2021 |
$602 |
| 2020 |
$630 |
| 2019 |
$473 |
| 2018 |
$493 |
| 2017 |
$228 |
| 2016 |
$151 |
| 2015 |
$106 |
| 2014 |
$109 |
| 2013 |
$97 |
| 2012 |
$91 |
| 2011 |
$49 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Total Current Assets
(Millions of US $) |
| 2024-06-30 |
$591 |
| 2024-03-31 |
$544 |
| 2023-12-31 |
$493 |
| 2023-09-30 |
$449 |
| 2023-06-30 |
$424 |
| 2023-03-31 |
$883 |
| 2022-12-31 |
$734 |
| 2022-09-30 |
$664 |
| 2022-06-30 |
$625 |
| 2022-03-31 |
$569 |
| 2021-12-31 |
$602 |
| 2021-09-30 |
$668 |
| 2021-06-30 |
$639 |
| 2021-03-31 |
$586 |
| 2020-12-31 |
$630 |
| 2020-09-30 |
$552 |
| 2020-06-30 |
$557 |
| 2020-03-31 |
$557 |
| 2019-12-31 |
$473 |
| 2019-09-30 |
$427 |
| 2019-06-30 |
$391 |
| 2019-03-31 |
$420 |
| 2018-12-31 |
$493 |
| 2018-09-30 |
$391 |
| 2018-06-30 |
$285 |
| 2018-03-31 |
$583 |
| 2017-12-31 |
$228 |
| 2017-09-30 |
$191 |
| 2017-06-30 |
$165 |
| 2017-03-31 |
$150 |
| 2016-12-31 |
$151 |
| 2016-09-30 |
$138 |
| 2016-06-30 |
$114 |
| 2016-03-31 |
$94 |
| 2015-12-31 |
$106 |
| 2015-09-30 |
$103 |
| 2015-06-30 |
$106 |
| 2015-03-31 |
$101 |
| 2014-12-31 |
$109 |
| 2014-09-30 |
$103 |
| 2014-06-30 |
$72 |
| 2014-03-31 |
$80 |
| 2013-12-31 |
$97 |
| 2013-09-30 |
$103 |
| 2013-06-30 |
$111 |
| 2013-03-31 |
$76 |
| 2012-12-31 |
$91 |
| 2012-09-30 |
$63 |
| 2012-06-30 |
$78 |
| 2012-03-31 |
$38 |
| 2011-12-31 |
$49 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.022B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
